Antengene has strategic partnerships with Celgene, one of the leading biopharmaceutical companies globally. Foundation of this partnership is our common interests in developing and introducing advanced medications to Asian countries and regions as well as shared passion in tackling medical and scientific challenges.


In April 2017, Celgene Corporation entered into a long-term partnership with Antengene by licensing rights to develop, manufacture and commercialize its TORC1/2 kinase inhibitor, CC-223 (ATG-008 for Antengene), in East and Southeast Asia.

This marks the first licensing deal for Celgene in the Asia-Pacific region, creates the foundation for a strategic partnership between the two companies and embodies the beginning of a long-term collaboration.